Skip to main content
Erschienen in: Current Breast Cancer Reports 1/2020

01.03.2020 | Breast Cancer Genetics (B Arun, Section Editor)

Variant of Uncertain Significance-Related Uncertainty in Breast Cancer Genomics

verfasst von: Sukh Makhnoon, Susan K Peterson

Erschienen in: Current Breast Cancer Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This paper considers the psychosocial implications of variant of uncertain significance (VUS)-derived uncertainty from the perspective of patients and providers and identifies potential uncertainty management strategies that can improve VUS-related clinical care.

Recent Findings

Based on the analysis of current research evidence around VUS-related medical management as well as provider and patient experiences of VUS-related uncertainty, we conclude that uncertainty around this new type of medical information is pervasive. Uncertainty appraisal varies across different contextual and situational factors—individual’s cancer diagnosis, provider’s experience with VUS, gene in which VUS has been identified, etc. Most importantly, strategies for uncertainty management that can address much of the VUS-related uncertainty also exist and offer hope for the thousands of VUS that will be returned to patients in genomic medicine clinics.

Summary

Uncertain sequencing results, when explained and relayed by experts in the presence of appropriate VUS-related reclassification and re-contact guidelines, increase the likelihood of maximal clinical and psychosocial benefit for patients without causing undue harm.
Literatur
1.
Zurück zum Zitat Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222–33.CrossRef Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222–33.CrossRef
2.
Zurück zum Zitat Maxwell KN, Hart SN, Vijai J, Schrader KA, Slavin TP, Thomas T, et al. Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancer. Am J Hum Genet. 2016;98(5):801–17.CrossRef Maxwell KN, Hart SN, Vijai J, Schrader KA, Slavin TP, Thomas T, et al. Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancer. Am J Hum Genet. 2016;98(5):801–17.CrossRef
3.
Zurück zum Zitat Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25–33.CrossRef Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25–33.CrossRef
4.
Zurück zum Zitat LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genetics in medicine : official journal of the American College of Medical Genetics. 2014;16(11):830–7.CrossRef LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genetics in medicine : official journal of the American College of Medical Genetics. 2014;16(11):830–7.CrossRef
5.
Zurück zum Zitat Shirts BH, Pritchard CC, Walsh T. Family-specific variants and the limits of human genetics. Trends Mol Med. 2016;22(11):925–34.CrossRef Shirts BH, Pritchard CC, Walsh T. Family-specific variants and the limits of human genetics. Trends Mol Med. 2016;22(11):925–34.CrossRef
6.
Zurück zum Zitat Selkirk CG, Vogel KJ, Newlin AC, Weissman SM, Weiss SM, Wang CH, et al. Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Familial Cancer. 2014;13(4):527–36.CrossRef Selkirk CG, Vogel KJ, Newlin AC, Weissman SM, Weiss SM, Wang CH, et al. Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Familial Cancer. 2014;13(4):527–36.CrossRef
7.
Zurück zum Zitat Lincoln SE, Yang S, Cline MS, Kobayashi Y, Zhang C, Topper S, et al. Consistency of BRCA1 and BRCA2 variant classifications among clinical diagnostic laboratories. JCO precision oncology. 2017;1. Lincoln SE, Yang S, Cline MS, Kobayashi Y, Zhang C, Topper S, et al. Consistency of BRCA1 and BRCA2 variant classifications among clinical diagnostic laboratories. JCO precision oncology. 2017;1.
8.
Zurück zum Zitat Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy M, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur D, Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–291. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy M, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur D, Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–291.
9.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(6):1480–90.CrossRef Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(6):1480–90.CrossRef
10.
Zurück zum Zitat Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005;14(7):1666–71.CrossRef Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005;14(7):1666–71.CrossRef
11.
Zurück zum Zitat Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. Jama. 2005;294(15):1925–33.CrossRef Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. Jama. 2005;294(15):1925–33.CrossRef
12.
Zurück zum Zitat Makhnoon S, Shirts BH, Bowen DJ, Fullerton SM. Hereditary cancer gene panel test reports: wide heterogeneity suggests need for standardization. Genetics in medicine : official journal of the American College of Medical Genetics. 2018;20(11):1438–45.CrossRef Makhnoon S, Shirts BH, Bowen DJ, Fullerton SM. Hereditary cancer gene panel test reports: wide heterogeneity suggests need for standardization. Genetics in medicine : official journal of the American College of Medical Genetics. 2018;20(11):1438–45.CrossRef
13.
Zurück zum Zitat Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. Am J Hum Genet. 2016;99(1):247.CrossRef Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. Am J Hum Genet. 2016;99(1):247.CrossRef
14.
Zurück zum Zitat Chang J, Seng S, Yoo J, Equivel P, Lum SS. Clinical management of patients at risk for hereditary breast cancer with variants of uncertain significance in the era of multigene panel testing. Ann Surg Oncol. 2019;26(10):3389–96.CrossRef Chang J, Seng S, Yoo J, Equivel P, Lum SS. Clinical management of patients at risk for hereditary breast cancer with variants of uncertain significance in the era of multigene panel testing. Ann Surg Oncol. 2019;26(10):3389–96.CrossRef
15.
Zurück zum Zitat Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, et al. Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes. Ann Surg Oncol. 2017;24(10):3067–72.CrossRef Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, et al. Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes. Ann Surg Oncol. 2017;24(10):3067–72.CrossRef
16.
Zurück zum Zitat Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, et al. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer medicine. 2018;7(6):2718–26.CrossRef Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, et al. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer medicine. 2018;7(6):2718–26.CrossRef
17.
Zurück zum Zitat Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, et al. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011;17(2):210–2.CrossRef Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, et al. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011;17(2):210–2.CrossRef
18.
Zurück zum Zitat Chern JY, Lee SS, Frey MK, Lee J, Blank SV. The influence of BRCA variants of unknown significance on cancer risk management decision-making. J Gynecol Oncol. 2019;30(4):e60.CrossRef Chern JY, Lee SS, Frey MK, Lee J, Blank SV. The influence of BRCA variants of unknown significance on cancer risk management decision-making. J Gynecol Oncol. 2019;30(4):e60.CrossRef
19.
Zurück zum Zitat Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR. Impact of multigene panel testing on surgical decision making in breast cancer patients. J Am Coll Surg. 2018;226(4):560–5.CrossRef Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR. Impact of multigene panel testing on surgical decision making in breast cancer patients. J Am Coll Surg. 2018;226(4):560–5.CrossRef
20.
Zurück zum Zitat Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA oncology. 2018;4(8):1066–72.CrossRef Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA oncology. 2018;4(8):1066–72.CrossRef
21.
Zurück zum Zitat Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132(2):428–33.CrossRef Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132(2):428–33.CrossRef
22.
Zurück zum Zitat Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(20):2232–9.CrossRef Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(20):2232–9.CrossRef
23.
Zurück zum Zitat Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K. Risk management decisions in women with BRCA1 and BRCA2 mutations. Am J Surg. 2018;215(5):899–903.CrossRef Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K. Risk management decisions in women with BRCA1 and BRCA2 mutations. Am J Surg. 2018;215(5):899–903.CrossRef
24.
Zurück zum Zitat Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test. 2002;6(2):107–13.CrossRef Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test. 2002;6(2):107–13.CrossRef
25.
Zurück zum Zitat • Macklin SK, Jackson JL, Atwal PS, Hines SL. Physician interpretation of variants of uncertain significance. Familial Cancer. 2019;18(1):121–6. This paper reports differences in physicians' interpretation of VUS.CrossRef • Macklin SK, Jackson JL, Atwal PS, Hines SL. Physician interpretation of variants of uncertain significance. Familial Cancer. 2019;18(1):121–6. This paper reports differences in physicians' interpretation of VUS.CrossRef
26.
Zurück zum Zitat Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST. A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study. Genetics in medicine : official journal of the American College of Medical Genetics. 2015;17(9):739–46.CrossRef Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST. A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study. Genetics in medicine : official journal of the American College of Medical Genetics. 2015;17(9):739–46.CrossRef
27.
Zurück zum Zitat Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. 2015;15:936.CrossRef Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. 2015;15:936.CrossRef
28.
Zurück zum Zitat Makhnoon S, Garrett LT, Burke W, Bowen DJ, Shirts BH. Experiences of patients seeking to participate in variant of uncertain significance reclassification research. Journal of community genetics. 2019;10(2):189–96.CrossRef Makhnoon S, Garrett LT, Burke W, Bowen DJ, Shirts BH. Experiences of patients seeking to participate in variant of uncertain significance reclassification research. Journal of community genetics. 2019;10(2):189–96.CrossRef
29.
Zurück zum Zitat Politi MC, Clark MA, Ombao H, Legare F. The impact of physicians' reactions to uncertainty on patients’ decision satisfaction. J Eval Clin Pract. 2011;17(4):575–8.CrossRef Politi MC, Clark MA, Ombao H, Legare F. The impact of physicians' reactions to uncertainty on patients’ decision satisfaction. J Eval Clin Pract. 2011;17(4):575–8.CrossRef
30.
Zurück zum Zitat Vos J, Gomez-Garcia E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ, et al. Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees’ perception, the medical impact by the pathogenic or uninformative BRCA1/2-result. Psycho-oncology. 2012;21(1):29–42.CrossRef Vos J, Gomez-Garcia E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ, et al. Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees’ perception, the medical impact by the pathogenic or uninformative BRCA1/2-result. Psycho-oncology. 2012;21(1):29–42.CrossRef
31.
Zurück zum Zitat O'Neill SC, DeMarco T, Peshkin BN, Rogers S, Rispoli J, Brown K, et al. Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. American journal of medical genetics Part C, Seminars in medical genetics. 2006;142c(4):251–9. O'Neill SC, DeMarco T, Peshkin BN, Rogers S, Rispoli J, Brown K, et al. Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. American journal of medical genetics Part C, Seminars in medical genetics. 2006;142c(4):251–9.
32.
Zurück zum Zitat van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(22):3672–7.CrossRef van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(22):3672–7.CrossRef
33.
Zurück zum Zitat Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A. The counsellees’ view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psycho-oncology. 2008;17(8):822–30.CrossRef Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A. The counsellees’ view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psycho-oncology. 2008;17(8):822–30.CrossRef
34.
Zurück zum Zitat Clift K, Macklin S, Halverson C, McCormick JB, Abu Dabrh AM, Hines S. Patients’ views on variants of uncertain significance across indications. Journal of community genetics. 2019. Clift K, Macklin S, Halverson C, McCormick JB, Abu Dabrh AM, Hines S. Patients’ views on variants of uncertain significance across indications. Journal of community genetics. 2019.
35.
Zurück zum Zitat Lumish HS, Steinfeld H, Koval C, Russo D, Levinson E, Wynn J, et al. Impact of panel gene testing for hereditary breast and ovarian cancer on patients. J Genet Couns. 2017;26(5):1116–29.CrossRef Lumish HS, Steinfeld H, Koval C, Russo D, Levinson E, Wynn J, et al. Impact of panel gene testing for hereditary breast and ovarian cancer on patients. J Genet Couns. 2017;26(5):1116–29.CrossRef
36.
Zurück zum Zitat Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Annals of oncology : official journal of the European Society for Medical Oncology. 2013;24 Suppl 8:viii69-viii74.CrossRef Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Annals of oncology : official journal of the European Society for Medical Oncology. 2013;24 Suppl 8:viii69-viii74.CrossRef
37.
Zurück zum Zitat •• Makhnoon S, Shirts BH, Bowen DJ. Patients’ perspectives of variants of uncertain significance and strategies for uncertainty management. J Genet Couns. 2019. This paper outlines a provisional VUS-related uncertainty management strategy. •• Makhnoon S, Shirts BH, Bowen DJ. Patients’ perspectives of variants of uncertain significance and strategies for uncertainty management. J Genet Couns. 2019. This paper outlines a provisional VUS-related uncertainty management strategy.
38.
Zurück zum Zitat Rosenthal EA, Ranola JMO, Shirts BH. Power of pedigree likelihood analysis in extended pedigrees to classify rare variants of uncertain significance in cancer risk genes. Familial Cancer. 2017;16(4):611–20.CrossRef Rosenthal EA, Ranola JMO, Shirts BH. Power of pedigree likelihood analysis in extended pedigrees to classify rare variants of uncertain significance in cancer risk genes. Familial Cancer. 2017;16(4):611–20.CrossRef
39.
Zurück zum Zitat Garrett LT, Hickman N, Jacobson A, Bennett RL, Amendola LM, Rosenthal EA, et al. Family studies for classification of variants of uncertain classification: current laboratory clinical practice and a new web-based educational tool. J Genet Couns. 2016;25(6):1146–56.CrossRef Garrett LT, Hickman N, Jacobson A, Bennett RL, Amendola LM, Rosenthal EA, et al. Family studies for classification of variants of uncertain classification: current laboratory clinical practice and a new web-based educational tool. J Genet Couns. 2016;25(6):1146–56.CrossRef
40.
Zurück zum Zitat Appelbaum PS, Parens E, Berger SM, Chung WK, Burke W. Is there a duty to reinterpret genetic data? The ethical dimensions. Genetics in medicine : official journal of the American College of Medical Genetics. 2019. Appelbaum PS, Parens E, Berger SM, Chung WK, Burke W. Is there a duty to reinterpret genetic data? The ethical dimensions. Genetics in medicine : official journal of the American College of Medical Genetics. 2019.
41.
Zurück zum Zitat Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature. 2018;562(7726):217–22.CrossRef Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature. 2018;562(7726):217–22.CrossRef
Metadaten
Titel
Variant of Uncertain Significance-Related Uncertainty in Breast Cancer Genomics
verfasst von
Sukh Makhnoon
Susan K Peterson
Publikationsdatum
01.03.2020
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 1/2020
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-020-00351-6

Weitere Artikel der Ausgabe 1/2020

Current Breast Cancer Reports 1/2020 Zur Ausgabe

Non-Invasive Breast Cancer Diagnosis and Treatment (ES Hwang, Section Editor)

Lobular Neoplasia

Non-Invasive Breast Cancer Diagnosis and Treatment (ES Hwang, Section Editor)

Multimodality Imaging of Ductal Carcinoma In Situ

Breast Cancer Genetics (B Arun, Section Editor)

Fertility Counseling and Preservation in Breast Cancer

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.